<h4>Background</h4>Ibrutinib is an oral irreversible inhibitor of Bruton's tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.